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Abstract
Most meningiomas are benign, but some clinical-aggressive tumors exhibit brain invasion and cannot be resected without
significant complications. To identify molecular markers for these clinically-aggressive meningiomas, we performed
microarray analyses on 24 primary cultures from 21 meningiomas and 3 arachnoid membranes. Using this approach,
increased transglutaminase 2 (TGM2) expression was observed, which was subsequently validated in an independent set of
82 meningiomas by immunohistochemistry. Importantly, the TGM2 expression level was associated with increasing WHO
malignancy grade as well as meningioma recurrence. Inhibition of TGM2 function by siRNA or cystamine induced
meningioma cell death, which was associated with reduced AKT phosphorylation and caspase-3 activation. Collectively,
these findings suggest that TGM2 expression increases as a function of malignancy grade and tumor recurrence and that
inhibition of TGM2 reduces meningioma cell growth.
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Introduction
Meningiomas are the second common primary tumor of the
central nervous system (CNS), accounting for 20 to 27% of CNS
tumors [1]. They arise from arachnoid cells of the leptomeninges
in the brain and spinal cord, and a recent study identified a
prostaglandin D synthase-positive meningeal precursor as the cell
of origin for meningioma [2]. The histology of the tumors are
diverse, and exhibit highly variable clinical characteristics [3].
Most meningiomas are benign, while some tumors are prone to
recurrence and cannot be treated without causing major
neurological deficits or even lethality.
Compared to other malignant brain tumors, there is relatively
little known about the molecular pathogenesis of meningioma or
the specific molecular changes that may have prognostic value or
represent targets for therapeutic drug design. NF2 gene deletion
and exposure to ionizing radiation are established risk factors,
while the role of sex hormones or head injury has been proposed,
but not proven. Substantial evidence from previous studies
indicated that the main genetic event in meningioma initiation is
inactivation of the NF2 gene, accounting for 30 to 70% of
sporadic meningiomas [4]. A recent genomic study in paired
progressive meningiomas also demonstrated that NF2 gene
inactivation is an early and frequent event in progressing
meningioma samples and is associated with higher chromosome
instability during progression [5]. Moreover, animal studies
showed that Nf2 loss in arachnoid cells is rate-limiting for
meningioma formation, additional inactivation of p16Ink4a
increases the frequency of meningioma [6]. The mice with both
Nf2 and Cdkn2ab inactivation lead to short latency of tumor
development and the ability to induce grade II/III meningioma
progression [7]. Furthermore, losses on chromosomes 1p, 9p, 10q,
and 14q as well as chromosomal gains on 12q, 17p, 17q, and 20q
have been implicated in the malignant progression of meningio-
mas [8]. Some studies also showed that genes such as TGF-b,
VEGF-A, hTERT, MMP2, MMP9 or TIMP-1 may also be
related to meningioma progression [9].
Recently, several studies using cDNA microarray analysis have
been reported and tried to unveil the association between gene
factors and tumor aggressiveness and to discover the biomarkers
for meningiomas [10]. However, the microarray results could vary
considerably due to different sample sources. The expression
pattern of meningiomas could be altered by intermixed with
normal tissue in surgical specimen or cell line with multiple
passages. Thus, in this study, we generated primary cultures of
human meningiomas to avoid contamination from other cells in
the specimen. The microarray analysis and immunohistochemical
staining revealed that transglutaminase 2 (TGM2) expression was
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Figure 1. Microarray analysis of human meningiomas. (A) Expression profiles of 24 samples, including 3 samples from arachnoid membranes
(green; Ara, WHO=0), 18 samples from benign meningiomas (pink; grade I, WHO=1), and 3 samples from atypical meningiomas (purple; grade II,
WHO=2). The heat map generated by hierarchical clustering revealed that the samples from arachnoid membranes clustered together. (type: A =
Arachnoid membrane, T = Meningioma; WHO: WHO grades; NF2: H= normal expression, L = low expression; SEX: M= male, F = female; AGE: 1,60,
2§60 y/o) (B) Comparison between arachnoid membranes and meningiomas identified 20 genes with significantly differential expression (fold
change .4; corrected p (FDR) ,0.05). (C) NF2 gene expression levels were different, with low expression in 13 meningiomas. (Group: Ara, Arachnoid
TGM2 in Meningioma
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increased in higher-grade meningiomas and in recurrent tumors.




The study was approved by the Institutional Review Board of
Chang Gung Memorial Hospital (IRB 98-3933B and 101-4601B).
A written informed consent was obtained from all participants.
Sample collection
Meningioma samples were acquired from surgical specimens.
Fresh tissues were harvested for primary cultures as described
below and/or were formalin-fixed for histological and immuno-
histochemical analyses. Clinical information was collected, includ-
ing demographic data, tumor location, treatment options and
prognosis.
Cell cultures
Fresh tumor tissues were immersed in culture medium
(Dulbecco’s modified Eagle medium (DMEM), Gibco), minced,
and digested with trypsin/EDTA. The cells were pelleted for
5 min at 1000 RPMs, re-suspended in DMEM with 10% fetal calf
serum, seeded evenly into 6-well plates, and incubated at 37uC in a
humidified atmosphere (5% CO2). Confluent cultures were split
using 0.05% trypsin/EDTA, and medium was changed twice a
week. The mRNA extractions and in vitro assays were performed
before passage 5, to avoid loss of original phenotype from long-
term passages.
Microarray analysis
RNA was prepared from primary cultures using an RNA
extraction kit (Geneaid, Taipei, Taiwan) following the standard
protocol. RNA quality and integrity were verified (RNA integrity
number.7). Expression profiling was carried out using Affymetrix
U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA), which contain
over 47,000 transcripts and variants, including 38,500 well-
characterized human genes. A total of 24 samples were assayed,
including 3 samples obtained from arachnoid membranes (Ara),
18 samples obtained from benign meningiomas (WHO grade I),
and 3 samples obtained from atypical meningiomas (WHO grade
II). Standard cDNA synthesis, probe labeling, hybridization, and
scanning of the arrays were performed using the standard
protocols in the Genomic Medicine Research Core Laboratory
(GMRCL) of Chang Gung Memorial Hospital as previously
described [11]. Basic microarray data visualization and data
filtering were accomplished as previously described [12,13].
The dCHIP program (build date-Dec 5, 2011) was used to
analyze the array data by comparing each group and performing
unsupervised tree-view clustering for all 24 array samples to
produce a dendrogram [14]. Sample groupings were established,
and invariant sets were normalized using median probe intensity
as the baseline array parameter. Model-based expression was
calculated using the Perfect Match/Mismatch difference model
method. Initially, multivariate analysis was performed using the
Compare Samples tool in which the mean Experimental/Base
(Tumor/Ara) expression ratio was greater than 1.2, the p-value for
a paired t-test was less than 0.05, and the samples were permuted
50 times to assess the false discovery rate. Filtered gene lists
consisting of 2547 transcripts were clustered by sample and gene
using the default parameters. The heat map generated by
hierarchical clustering revealed that the samples from arachnoid
membranes clustered together and fell into the group of tumors
with high NF2 expression (Figure 1).
Immunohistochemistry (IHC)
Tissue specimens or cultured cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for IHC
analyses. Paraffin-embedded tissue sections from a different cohort
(n = 82, WHO grade I = 58, grade II = 21, and grade III = 3) were
immunostained using previously described conditions. Briefly, the
sections were de-paraffinized using xylene, rehydrated and blocked
with 2% goat serum. Samples were subsequently incubated with
primary antibody overnight at 4uC and secondary antibody
conjugated to Horseradish Peroxidase (HRP) at room temperature
for 1 hour. The signals were visualized with an HRP substrate.
The following primary antibodies were used: polyclonal rabbit
anti-GFAP (glial fibrillary astrocytic protein) (Chemicon Interna-
tional, Temecula, CA), monoclonal mouse anti-EMA (epithelial
membrane antigen) (Thermo Scientific, Rockford, IL), polyclonal
rabbit anti-S100 and monoclonal mouse anti-vimentin (Dako,
Denmark) antibodies. Transglutaminase 2 (TGM2) antibody was
purchased from Abcam (Cambridge, UK). At least 4 high-power
fields (HPF, 400x) were randomly photographed from the tumor
region. In each HPF, individual cell counts were made by single
observer and mean percentage were recorded as %/HPF.
Immunoblot analysis
Meningioma cells were harvested by washing cell layers twice in
cold PBS and then lysed with RIPA buffer (50 mM Tris, pH 8.0,
150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate acid, 0.1%
SDS and 2 mM EDTA) containing phosphatase inhibitors (2 mM
sodium orthovanadate, 50 mM sodium fluoride and 50 nM
calyculin A) and a 16complete protease inhibitor cocktail (Roche
Molecular Biochemicals, Indianapolis, IN). The cell lysates were
incubated for 30 min on ice, clarified by centrifugation (13,0006g)
and re-suspended in 16 sample buffer (33% glycerol, 6.7% SDS,
330 mM dithiothreitol). Proteins were resolved by SDS-PAGE,
transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA)
and subjected to immunoblot analysis using the appropriate
antibodies, HRP-conjugated secondary antibodies and the en-
hanced chemiluminescence (ECL) detection systems (GE, Fair-
field, CT). Relative expression levels were quantified on a GS-800
Calibrated Densitometer (BioRad), and p-values were determined
using a paired Student’s t-test. Antibodies for cleaved and total
caspase-3, phospho- and total AKT, and a-tubulin were
purchased from Santa Cruz Biotechnology and Cell Signaling
Technology.
Cell viability assay
Cell viability was tested by a 3-(4,5dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-based survival assay (Sigma-
Aldrich, St. Louis, MO. USA) as published previously. Briefly,
MTT (5 mg/ml) was added to the medium in 96-well plates
containing 2500 meningioma cells; after 4 hours, the medium was
removed and DMSO was added. The optical density at 540 nm
was detected by an ELISA reader (Infinite M200 Pro, Tecan,
Switzerland).
membrane; NF2-H and NF2-L, meningiomas with normal and low NF2 expression, respectively) (D) TGM2 expression was inversely correlated with
NF2 gene expression. (Pearson correlation coefficient r =20.5313, r2 = 0.2823, p = 0.0132).
doi:10.1371/journal.pone.0108228.g001
TGM2 in Meningioma
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siRNA transfection
For in vitro gene knockdown experiments, siRNAs (FlexiTube
siRNA: Hs_TGM2_1, 2, 5, 6, 7) were purchased from Qiagen
(Venlo, Netherlands). The transfection was performed according
to the standard protocol from manufacturer [15]. Briefly, culture
medium was replaced with serum-free medium before mixture
with the diluted siRNAs along with lipofectamin 2000 (Invitrogen,
Calsbad, CA, USA) for 4 hours; then change medium with 10%
serum and extracted RNA/protein after 24–72 hours as described
previously. The knockdown efficiency was calculated using real-
time quantitative PCR using specific primers and SYBR Green I
Master reagent with Lightcycler 480 (Roche Diagnostics, Mann-
heim, Germany).
Statistical analyses
Standard statistical analyses were used to test the difference
among groups. All data were expressed as mean 6 SD and a p
value lower than.05 was considered significant. Data were
analyzed by using commercially available statistical software SPSS
(SPSS Inc, Chicago, IL) and GraphPad Prism (GraphPad
Software Inc. La Jolla, CA). All in vitro experiments were
performed at least three times with similar results.
Results
Human meningioma cultures
For this study, we established primary meningioma cultures
comprised of epithelial-like cells expressing vimentin [16],
epithelial membrane antigen (EMA) [17], and S100b [18], but
not glial fibrillary astrocytic protein (GFAP) (Figure S1 in File S1).
All mRNA extractions and in vitro assays were performed before
passage 5 to avoid loss of the original phenotype from long-term
passage.
Expression profiling
The 24 samples used for microarray analysis included 3 from
arachnoid membranes (green; Ara, WHO=0), 18 from benign
meningiomas (pink; grade I, WHO=1), and 3 from atypical
meningiomas (purple; grade II, WHO=2). The clinical informa-
tion is listed in Table S1 in File S1. The heat map generated by
hierarchical clustering revealed a differential expression pattern of
2547 transcripts in 24 samples after multivariate analysis
(Figure 1A). Interestingly, samples from arachnoid membrane
and those with NF2 gene expression clustered together. Further
analysis was performed with MATLAB version (R2013a) using the
‘‘mafdr’’ command to calculate the estimate false discovery rate
(FDR) for multiple hypothesis testing of comparison between
arachnoid membranes and meningiomas. The 20 genes with
significantly differential expression were listed in Table 1 and the
heat map was generated by hierarchical clustering (Figure 1B).
Compared with the arachnoid membranes, TGM2 gene expres-
sion was 11.33-fold higher in meningiomas (p=0.001429; FDR
p=0.034055289). Besides, NF2 gene expression was low in 13 of
the 21 meningiomas analyzed (Figure 1C). TGM2 gene expression
was inversely correlated with NF2 gene expression (r2= 0.2823,
p = 0.0132) (Figure 1D).
TGM2 expression in meningiomas
From the microarray analysis, we choose TGM2 for further
study, because TGM2 has been reported as a prognostic marker
for laryngeal cancer [19] or colorectal cancer [20] as well as a
chemotherapy-resistance marker for breast cancer [21] and lung
Table 1. Fold change and statistical significance for genes differentially expressed between Arachnoid membranes and
Meningiomas.
Probeset ID Gene Symbol Fold Change P P (FDR)*
236896_at ZIC1 23.37 0.025576 0.049611751
206343_s_at NRG1 5.79 0.002985 0.030487365
205303_at KCNJ8 6.55 0.00062 0.031028682
213438_at NFASC 9.88 0.000319 0.031929514
205681_at BCL2A1 7.63 0.001923 0.029163321
209047_at AQP1 8.36 0.002824 0.030724052
237737_at LOC401131 8.51 0.000658 0.027442033
209710_at GATA2 8.14 0.002164 0.030083364
201422_at IFI30 7.73 0.001366 0.040213643
203821_at HBEGF 7.73 0.000549 0.030528219
202901_x_at CTSS 8.15 0.004221 0.034630372
201042_at TGM2 11.33 0.001429 0.034055289
213712_at ELOVL2 16.62 0.004042 0.034877067
206858_s_at HOXC6 18.38 0.000098 0.016348445
240167_at LOC152742 18.89 0.001614 0.032309866
218404_at SNX10 18.32 0.000094 0.023521743
220088_at C5AR1 35.59 0.002852 0.030368497
205098_at CCR1 38.14 0.005182 0.036019406
201721_s_at LAPTM5 60.22 0.004092 0.034710051
209875_s_at SPP1 160.42 0.00009 0.045041635
*The estimate false discovery rate (FDR) for multiple hypothesis testing were performed with MATLAB version (R2013a) using the ‘‘mafdr’’ command.
doi:10.1371/journal.pone.0108228.t001
TGM2 in Meningioma
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e108228
cancer [22]. The inhibition of TGM2 may impair cell proliferation
and induced apoptosis in gliomas [23,24]. To validate the
significance of differential expression of TGM2, a total of 82
meningioma samples were immunostained with a TGM2 antibody
and quantified by microscopy under a 400X high power field
(HPF) system (illustrated in Figure 2A and 2B). Abundant TGM2
expression (defined by .50% TGM2 immunopositive cells) was
detected in all grade II and III meningiomas (Figure 2C). The
expression level was correlated well with the WHO grading
(ANOVA, p=0.0046). For grade I meningioma, high TGM2
expression (.50%) was observed in those with recurrence, while
benign tumors had low TGM2 expression, suggesting that TGM2
expression may induce more aggressive tumor behavior (Fig-
ure 2D).
TGM2 inhibition induces cell death
Since the TGM2 expression was high in meningiomas and
associated with the aggressive tumor behavior, we reasoned that
TGM2 inhibition might be a therapeutic target for meningioma.
For specific inhibition of TGM2 gene expression, we apply
FlexiTube GeneSolution GS7052 for TGM2 from Qiagen, which
contains Hs_TGM2_1, 5, 6, 7 clones [15]. The mixture of siRNA
yielded an efficient knockdown of TGM2 expression in a dose
dependent manner (Figure 3A). Treatment of meningioma cells
with 5 nM siRNA decreased TGM2 mRNA expression by 80–
90% 2 days after transfection by quantitative RT-PCR and
resulted in a 30% reduction in cell survival (Figure 3B).
Furthermore, TGM2 inhibition by siRNA induced meningioma
cell apoptosis (TUNEL + cells; Figure 3C and 3D).
We next tested the effect of cystamine in meningioma cells.
Cystamine is an orally active competitor of transglutaminase,
which blocks access to the active site of the enzyme. TGM2
inhibitors have been reported as a treatment modality for various
conditions, such as celiac sprue, Huntington’s disease, and certain
types of cancer [25]. Treatment of meningioma cells decreased
survival in a dose-dependent fashion (Figure 4A). Meningioma cell
viability reduced to a maximum of 39.6% of control after 48-hour
of cystamine treatment.
To determine the molecular mechanism of cell death induced
by genetic or pharmacological inhibition of TGM2, we initially
examined caspase-3 activation. Treatment of meningioma cells
with cystamine induced caspase-3 activation by 1.5-fold (Fig-
ure 4B and 4C), which was associated with a reduction in
activated (phosphorylated) AKT expression.
Figure 2. Validation of TGM2 by immunohistochemical study. TGM2 immunohistochemistry (IHC) was performed on 82 meningiomas from a
different cohort (n = 82, WHO grade I = 58, grade II = 21, and grade III = 3). The IHC images represented high (A) and low (B) expression of TGM2,
respectively. Scale bar = 50 mm. (C) The quantification of TGM2 expression was expressed by percentage of TGM2-immunopositive cell per high
power field (%HPF). The dot plot showed that TGM2 expression was abundant (positive in .50% of cells) in all grade II and III meningiomas. The
TGM2 expression level was correlated with increased WHO malignancy grade (ANOVA, p= 0.0046). (D) The dot blot for TGM2 expression in grade I
meningiomas revealed that those tumors with recurrence had high TGM2 expression (positive in .70% of cells).
doi:10.1371/journal.pone.0108228.g002
TGM2 in Meningioma
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Discussion
Meningiomas are unique tumors of central nervous system and
are understudied in comparison with malignant gliomas. Employ-
ing high-throughput microarray analyses, genes and pathways
associated with tumorigenesis, clinical progression, response to
treatment, and environmental exposure, can be discovered,
leading to the development of new biomarkers and therapeutic
targets. A few microarray studies of meningiomas in recent years
with different aims and approaches have identified several targets;
however, few commonly de-regulated genes have been identified
[10]. One possible reason for the results may be various sources for
sample preparation, in which tissue heterogeneity of surgical
specimen can confound the interpretation of gene expression data.
The surgical specimens contain not only tumor cells but also
tumor vasculature, inflammatory cells, circulating leukocytes, and
fibroblasts, while tumor cells are the dominant component of the
primary culture. Although a previous expression profiling study
comparing the fresh frozen specimen with meningioma cultures in
passage 5 or 10 revealed dozens of differentially-expressed genes
[26], our study using primary meningioma cultures with passage 3
has the advantage of homogenous cell type and closer to original
tumor properties. Consistent with our finding of TGM2 upregula-
tion in aggressive meningiomas, the microarray dataset GSE32197
from public GEO (Gene Expression Ominbus database, NIH,
USA; http://www.ncbi.nlm.nih.gov/geo/) also revealed an 8-fold
increase in TGM2 expression in anaplastic meningioma relative to
low-grade fibroblastic meningioma (Figure S2 in File S1) [27].
Transglutaminase 2 is a multi-functional enzyme that post-
translationally modifies proteins by catalyzing the formation of
intermolecular isopeptide bonds between glutamine and lysine
side-chains. It plays a role in diverse biological functions, and is
believed to participate in the pathogenesis of several unrelated
diseases, including celiac sprue, neurodegenerative diseases, and
certain types of cancer [28]. Recent studies showed that
upregulation of TGM2 was associated with poor prognosis in
hepatocellular carcinoma [29], colorectal cancer [20], non-small
cell lung cancer [30], or laryngeal cancer [19]. Moreover, it had
been reported as a chemotherapy-resistance marker for breast
cancer [21] or lung cancer [22]. In addition, we analyzed the data
publicly available at the REMBRANDT database (REpository of
Molecular BRAin Neoplasia DaTa, NCI, NIH, USA; https://
wiki.nci.nih.gov/display/icrportals/REMBRANDT). The patient
survival data mining demonstrated significant detrimental effect of
Figure 3. TGM2 inhibition by siRNA treatment induces cell apoptosis. (A) Quantitative RT-PCR using SYBR Green was used to assay TGM2
mRNA expression in siRNA-treated cells. Meningioma cells treated with TGM2 siRNA exhibited reduced TGM2 expression in a dose-dependent
manner (.80% in 5 nM siRNA). (B) Cell viability assessed using the MTT assay showed 30% decrease of cell survival following 5 nM siRNA exposure.
(C) and (D) TUNEL assays were used to measure apoptosis following 5 nM siRNA treatment. Quantification expressed by the number of TUNEL-
positive per high power field, demonstrated that TGM2 siRNA treatment increased meningioma cell apoptosis (unpaired Student’s t-test, p = 0.0021).
doi:10.1371/journal.pone.0108228.g003
TGM2 in Meningioma
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TGM2 upregulation in glioma with a Log-rank p-value of 0.0068.
Furthermore, TGM2 inhibitor such as cystamine, glucosamine, or
KCC009 effectively promote cell death in glioma [31], breast
cancer [32], or pancreatic cancer [33]. These findings and our
results suggest that TGM2 upregulation is associated with
aggressive behavior of various tumors and may be a therapeutic
target for some kinds of cancers.
Transglutaminase 2 is abundantly expressed in many tissues and
widely distributed in various parts of a cell, including the
extracellular matrix, plasma membrane, cytosol, mitochondria,
and nucleus. It exerts opposing effects on cell growth, differenti-
ation and apoptosis via multiple activities, including transamidase,
GTPase, cell adhesion, protein disulfide isomerase, kinase and
scaffold activities. The exact role of TGM2 in tumor formation is
yet to be elucidated but several mechanisms are proposed. TGM2
can activate NF-kB and focal adhesion kinase (FAK) tyrosine
kinase, in turn activate anti-apoptotic pathways to allow cancer
cells to become immortalized [25]. In agreement with our findings
of caspase-3 activation and reduced phosphorylation of Akt, a
previous study showed that the TGM2 inhibitor KCC009
decreased Akt phosphorylation and upregulated the expression
of the pro-apoptotic protein Bim, resulting in enhanced cell
apoptosis in cultured mouse glioblastoma cell line [34].
In the present study, upregulation of TGM2 gene expression in
meningiomas was identified by expression profiling, analysis of
primary meningioma cultures, and immunohistochemical analyses
using a distinct set of meningiomas all support the idea that TGM2
expression increases in a malignancy grade-dependent manner.
We also demonstrated that inhibition of TGM2 decreased
meningioma cell growth. Future studies focused on this interesting
enzyme may lead to new treatment options for patients with this
common CNS malignancy.
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